Cellectar announces positive pivotal trial data for iopofosine I 131 in WM

Cellectar Biosciences, Inc.

CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.
Overall response rate of 75.6% and 100% disease control in heavily pretreated, BTKi-refractory WM patients.
Median duration of response not yet reached at median 8-month follow-up; 76% remain progression-free.
No treatment-related discontinuations or deaths; Grade 3+ cytopenias manageable with no bleeding or febrile neutropenia beyond 2%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.